RÉSUMÉ
BACKGROUND: FGFR genomic aberrations occur in approximately 5-10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecological, and other rare cancers. However, its efficacy and safety in Asian patients remain largely unknown. We conducted a multicenter, open-label, single-arm phase IIa study of erdafitinib to evaluate its efficacy in Asian patients with FGFR-altered advanced cholangiocarcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer. METHODS: Patients with pathologically/cytologically confirmed, advanced, or refractory tumors who met molecular and study eligibility criteria received oral erdafitinib 8 mg once daily with an option for pharmacodynamically guided up-titration to 9 mg on a 28-day cycle, except for four NSCLC patients who received erdafitinib 10 mg (7 days on/7 days off) as they were recruited before the protocol amendment. The primary endpoint was investigator-assessed objective response rate per RECIST v1.1. Secondary endpoints included progression-free survival, duration of response, disease control rate, overall survival, safety, and pharmacokinetics. RESULTS: Thirty-five patients (cholangiocarcinoma: 22; NSCLC: 12; esophageal cancer: 1) were enrolled. At data cutoff (November 19, 2021), the objective response rate for patients with cholangiocarcinoma was 40.9% (95% CI, 20.7-63.6); the median progression-free survival was 5.6 months (95% CI, 3.6-12.7) and median overall survival was 40.2 months (95% CI, 12.4-not estimable). No patient with RET/FGFR-altered NSCLC achieved objective response and the disease control rate was 25.0% (95% CI, 5.5-57.2%), with three patients with stable disease. The single patient with esophageal cancer achieved partial response. All patients experienced treatment-emergent adverse events, and grade ≥ 3 treatment-emergent adverse events were reported in 22 (62.9%) patients. Hyperphosphatemia was the most frequently reported treatment-emergent adverse event (all-grade, 85.7%). CONCLUSIONS: Erdafitinib demonstrated efficacy in a population of Asian patients in selected advanced solid tumors, particularly in those with advanced FGFR-altered cholangiocarcinoma. Treatment was tolerable with no new safety signals. TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov (NCT02699606); study registration (first posted): 04/03/2016.
Sujet(s)
Carcinome pulmonaire non à petites cellules , Cholangiocarcinome , Pyrazoles , Humains , Femelle , Mâle , Adulte d'âge moyen , Sujet âgé , Cholangiocarcinome/traitement médicamenteux , Cholangiocarcinome/génétique , Cholangiocarcinome/anatomopathologie , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Carcinome pulmonaire non à petites cellules/génétique , Carcinome pulmonaire non à petites cellules/anatomopathologie , Pyrazoles/usage thérapeutique , Pyrazoles/administration et posologie , Pyrazoles/effets indésirables , Adulte , Quinoxalines/usage thérapeutique , Quinoxalines/administration et posologie , Quinoxalines/effets indésirables , Tumeurs du poumon/traitement médicamenteux , Tumeurs du poumon/génétique , Tumeurs du poumon/anatomopathologie , Tumeurs de l'oesophage/traitement médicamenteux , Tumeurs de l'oesophage/anatomopathologie , Tumeurs de l'oesophage/génétique , Récepteur facteur croissance fibroblaste/antagonistes et inhibiteurs , Récepteur facteur croissance fibroblaste/génétique , Asiatiques , Tumeurs des canaux biliaires/traitement médicamenteux , Tumeurs des canaux biliaires/anatomopathologie , Survie sans progression , Sujet âgé de 80 ans ou plusRÉSUMÉ
Intrahepatic cholangiocarcinoma (ICC) is the second commonly-seen liver malignancy and one of the most fatal cancers in Taiwan. Survival after diagnosis of ICC remains poor. This study aimed to investigate the survival and prognostic factors in patients with ICC. All patients with newly diagnosed ICC during 2004 to 2018 were identified from a national cancer database and followed until December 2020. Estimates of overall survival (OS) were conducted using the Kaplan-Meier method and Cox proportional hazards model. Hazard ratios with 95% confidence intervals were calculated. Initially, 7940 patients with ICC disease (stage IV: 55.6%, 4418/7940) were eligible for this study. Only 32.3% (2563/7940) patients with ICC underwent liver resection. After Propensity score matching, 969 pairs (N = 1938) of patients were matched and selected (mean age 62.8 ± 11.0 years, 53.1% were male, 29.7% had cirrhosis). The median follow-up time was 80.0 months (range 25-201 months). The 3-, 5-year OS rates were 44.0%, 36.4% in the surgical group and 26.0%, 23.7% in the non-surgical group, respectively. Surgery, young patients (≤ 54 years), small tumor size, no vascular invasion and chemotherapy were associated with better OS in patients with stages I-III disease. Surgery benefit was maximum in stage I disease followed by stage II. In patients with stage IV disease, factors such as surgery, young patients (≤ 64 years), single tumor, and no vascular invasion were associated with better OS. Chemotherapy was insignificantly associated with better OS. Long-term survival in patients with ICC is very poor. Compared to non-surgical patients, surgery conveys approximately 18% and 12% better OS rates at 3-year and 5-year, respectively. Early detection and surgical intervention may improve OS substantially in patients with ICC.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Humains , Cholangiocarcinome/mortalité , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/chirurgie , Cholangiocarcinome/thérapie , Mâle , Femelle , Adulte d'âge moyen , Tumeurs des canaux biliaires/mortalité , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/thérapie , Pronostic , Sujet âgé , Taïwan/épidémiologie , Taux de survie , Estimation de Kaplan-Meier , Modèles des risques proportionnels , Score de propension , Stadification tumorale , HépatectomieRÉSUMÉ
Cholangiocarcinoma (CCA) is a rare type of digestive tract cancer originating from the epithelial cells of the liver and biliary tract. Current treatment modalities for CCA, such as chemotherapy and radiation therapy, have demonstrated limited efficacy in enhancing survival rates. Despite the revolutionary potential of immunotherapy in cancer management, its application in CCA remains restricted due to the minimal infiltration of immune cells in these tumors, rendering them cold and unresponsive to immune checkpoint inhibitors (ICIs). Cancer cells within cold tumors deploy various mechanisms for evading immune attack, thus impeding clinical management. Recently, combination immunotherapy has become increasingly essential to comprehend the mechanisms underlying cold tumors to enhance a deficient antitumor immune response. Therefore, a thorough understanding of the knowledge on the combination immunotherapy of cold CCA is imperative to leverage the benefits of immunotherapy in treating patients. Moreover, gut microbiota plays an essential role in the immunotherapeutic responses in CCA. In this review, we summarize the current concepts of immunotherapy in CCA and clarify the intricate dynamics within the tumor immune microenvironment (TIME) of CCA. We also delve into the evasion mechanisms employed by CCA tumors against the anti-tumor immune responses. The context of combination immunotherapies in igniting cold tumors of CCA and the critical function of gut microbiota in prompting immune responses have also been annotated. Furthermore, we have proposed future directions in the realm of CCA immunotherapy, aiming to improve the clinical prognosis of CCA patients.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Immunothérapie , Microenvironnement tumoral , Humains , Cholangiocarcinome/thérapie , Cholangiocarcinome/immunologie , Cholangiocarcinome/anatomopathologie , Microenvironnement tumoral/immunologie , Tumeurs des canaux biliaires/thérapie , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/immunologie , Inhibiteurs de points de contrôle immunitaires/usage thérapeutique , Microbiome gastro-intestinalRÉSUMÉ
BACKGROUND: Cholangiocarcinoma (CCA) is one of the most deadly cancers in the world. It usually has a bad prognosis and is challenging to identify in its early stages. Long noncoding RNAs (lncRNAs) have been shown in an increasing number of studies to be important in the control of signaling pathways, cell behaviors, and epigenetic modification that contribute to the growth of tumors. The purpose of this work was to examine the relationship between CCA and lncRNA AL161431.1. METHODS: Using TCGA clinical survival data, we evaluated the association between AL161431.1 expression and patient prognosis. Using the program cluster Profiler R, enrichment analysis was performed. Additionally, the association between immune cell infiltration and AL161431.1 expression was evaluated by a review of the TCGA database. Next, to ascertain if AL161431.1 influences tumor growth, migration, and invasion in CCA, functional in vitro assays were conducted. Quantitative real-time polymerase chain reaction (qPCR) was employed to gauge AL161431.1 expression levels in CCA cells. Western blot was used to measure protein levels. RESULTS: In CCA, AL161431.1 was extremely expressed. The patients in the high-risk group had a significantly poorer overall survival (OS) than the patients in the low-risk group. A more thorough look at the TCGA data showed a relationship between high expression levels of AL161431.1 and increased infiltration of T cells, T helper cells, and NK CD56dim cells. Furthermore, AL161431.1 knockdown in CCA cells impeded invasion, migration, and proliferation and also lowered the expression of phosphorylated Smad2/Smad3 to restrain the TGFß/SMAD signaling pathway. CONCLUSIONS: Our results indicate that the lncRNA AL161431.1 activates the TGFß/SMAD signaling pathway to enhance CCA development and metastasis. AL161431.1 could be a novel target for cholangiocarcinoma treatment or a diagnostic marker.
Sujet(s)
Tumeurs des canaux biliaires , Mouvement cellulaire , Cholangiocarcinome , Évolution de la maladie , Régulation de l'expression des gènes tumoraux , ARN long non codant , Cholangiocarcinome/génétique , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/métabolisme , Humains , ARN long non codant/génétique , ARN long non codant/métabolisme , Tumeurs des canaux biliaires/génétique , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/métabolisme , Lignée cellulaire tumorale , Mouvement cellulaire/génétique , Prolifération cellulaire/génétique , Techniques de knock-down de gènes , Pronostic , Femelle , Mâle , Invasion tumoraleRÉSUMÉ
BACKGROUND: Whether endobiliary radiofrequency ablation (EB-RFA) changes the standard role of stent placement in treating unresectable malignant biliary obstruction (MBO) remains unclear. The aim of this study is to compare percutaneous EB-RFA and metal stent placement (RFA-Stent) with metal stent placement alone (Stent) in treating unresectable MBO using a propensity score matching (PSM) analysis. METHODS: From June 2013 to June 2018, clinical data from 163 patients with malignant biliary obstruction who underwent percutaneous RFA-Stent or stenting alone were retrospectively analyzed using a nearest-neighbor algorithm to one-to-one PSM analysis to compare primary and secondary stent patency (PSP, SSP), overall survival (OS) and complications between the two groups. RESULTS: Before matching, for whole patients, RFA-Stent resulted in longer median PSP (8.0 vs. 5.1 months, P = 0.003), SSP (9.8 vs. 5.1 months, P < 0.001) and OS (7.0 vs. 4.5 months, P = 0.034) than the Stent group. After matching (54 pairs), RFA-Stent also resulted in better median PSP (8.5 vs. 5.1 months, P < 0.001), SSP (11.0 vs. 6.0 months, P < 0.001), and OS (8.0 vs. 4.0 months, P = 0.007) than Stent. RFA-Stent was comparable with Stent for complication rates. In Cox analysis, RFA-Stent modality and serum total bilirubin level were independent prognostic factors for PSP. RFA-Stent modality, performance status score and combination therapy after stent were independent prognostic factors for OS. CONCLUSION: Percutaneous RFA-Stent was superior to Stent in terms of PSP, SSP, and OS in selected patients with unresectable MBO.
Sujet(s)
Cholestase , Score de propension , Ablation par radiofréquence , Endoprothèses , Humains , Études rétrospectives , Mâle , Femelle , Sujet âgé , Cholestase/étiologie , Cholestase/chirurgie , Ablation par radiofréquence/méthodes , Adulte d'âge moyen , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/chirurgie , Résultat thérapeutique , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: Intermediate cell carcinoma (Int-CA) is a rare and enigmatic primary liver cancer characterized by uniform tumor cells exhibiting mixed features of both HCC and intrahepatic cholangiocarcinoma. Despite the unique pathological features of int-CA, its molecular characteristics remain unclear yet. METHODS: RNA sequencing and whole genome sequencing profiling were performed on int-CA tumors and compared with those of HCC and intrahepatic cholangiocarcinoma. RESULTS: Int-CAs unveiled a distinct and intermediate transcriptomic feature that is strikingly different from both HCC and intrahepatic cholangiocarcinoma. The marked abundance of splicing events leading to intron retention emerged as a signature feature of int-CA, along with a prominent expression of Notch signaling. Further exploration revealed that METTL16 was suppressed within int-CA, showing a DNA copy number-dependent transcriptional deregulation. Notably, experimental investigations confirmed that METTL16 suppression facilitated invasive tumor characteristics through the activation of the Notch signaling cascade. CONCLUSIONS: Our results provide a molecular landscape of int-CA featured by METTL16 suppression and frequent intron retention events, which may play pivotal roles in the acquisition of the aggressive phenotype of Int-CA.
Sujet(s)
Carcinome hépatocellulaire , Cholangiocarcinome , Analyse de profil d'expression de gènes , Tumeurs du foie , Humains , Tumeurs du foie/génétique , Tumeurs du foie/anatomopathologie , Carcinome hépatocellulaire/génétique , Carcinome hépatocellulaire/anatomopathologie , Cholangiocarcinome/génétique , Cholangiocarcinome/anatomopathologie , Transcriptome , Mâle , Methyltransferases/génétique , Methyltransferases/métabolisme , Transduction du signal/génétique , Régulation de l'expression des gènes tumoraux , Tumeurs des canaux biliaires/génétique , Tumeurs des canaux biliaires/anatomopathologie , Femelle , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Cholangiocarcinoma (CCA) features highly desmoplastic stroma that promotes structural and functional resistance to therapy. Lysyl oxidases (LOX, LOXL1-4) catalyze collagen cross-linking, thereby increasing stromal rigidity and facilitating therapeutic resistance. Here, we evaluate the role of lysyl oxidases in stromal desmoplasia and the effects of pan-lysyl oxidase (pan-LOX) inhibition in CCA. METHODS: Resected CCA and normal liver specimens were analyzed from archival tissues. Spontaneous and orthotopic murine models of intrahepatic CCA (iCCA) were used to assess the impact of the pan-LOX inhibitor PXS-5505 in treatment and correlative studies. The functional role of pan-LOX inhibition was interrogated through in vivo and ex vivo assays. RESULTS: All 5 lysyl oxidases are upregulated in CCA and reduced lysyl oxidase expression is correlated with an improved prognosis in resected patients with CCA. Spontaneous and orthotopic murine models of intrahepatic cholangiocarcinoma upregulate all 5 lysyl oxidase isoforms. Pan-LOX inhibition reversed mechanical compression of tumor vasculature, resulting in improved chemotherapeutic penetrance and cytotoxic efficacy. The combination of chemotherapy with pan-LOX inhibition increased damage-associated molecular pattern release, which was associated with improved antitumor T-cell responses. Pan-LOX inhibition downregulated macrophage invasive signatures in vitro, rendering tumor-associated macrophages more susceptible to chemotherapy. Mice bearing orthotopic and spontaneously occurring intrahepatic cholangiocarcinoma tumors exhibited delayed tumor growth and improved survival following a combination of pan-LOX inhibition with chemotherapy. CONCLUSIONS: CCA upregulates all 5 lysyl oxidase isoforms, and pan-LOX inhibition reverses tumor-induced mechanical forces associated with chemotherapy resistance to improve chemotherapeutic efficacy and reprogram antitumor immune responses. Thus, combination therapy with pan-LOX inhibition represents an innovative therapeutic strategy in CCA.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Lysyloxidase , Cholangiocarcinome/traitement médicamenteux , Cholangiocarcinome/anatomopathologie , Animaux , Tumeurs des canaux biliaires/traitement médicamenteux , Tumeurs des canaux biliaires/anatomopathologie , Lysyloxidase/antagonistes et inhibiteurs , Souris , Humains , Microenvironnement tumoral/effets des médicaments et des substances chimiques , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Antinéoplasiques/usage thérapeutique , Antinéoplasiques/pharmacologie , Mâle , Amino-acid oxidoreductases/antagonistes et inhibiteurs , Modèles animaux de maladie humaine , Lignée cellulaire tumoraleRÉSUMÉ
We present a combination of distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail. This clinical case is unique. When analyzing the literature, we found no any case of similar primary multiple malignant tumor. Importantly, final diagnosis of simultaneous malignant pancreatobiliary neoplasia is possible only via intraoperative biopsy after adequate morphological dissection and research of resected organ complex including molecular genetic analysis due to identical histological and immunohistochemical picture of ductal neoplasia.
Sujet(s)
Adénocarcinome mucineux , Carcinome du canal pancréatique , Cholangiocarcinome , Tumeurs primitives multiples , Humains , Cholangiocarcinome/diagnostic , Cholangiocarcinome/chirurgie , Cholangiocarcinome/anatomopathologie , Tumeurs primitives multiples/chirurgie , Tumeurs primitives multiples/anatomopathologie , Tumeurs primitives multiples/diagnostic , Carcinome du canal pancréatique/chirurgie , Carcinome du canal pancréatique/diagnostic , Carcinome du canal pancréatique/anatomopathologie , Adénocarcinome mucineux/diagnostic , Adénocarcinome mucineux/chirurgie , Adénocarcinome mucineux/anatomopathologie , Mâle , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/diagnostic , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs du pancréas/chirurgie , Tumeurs du pancréas/diagnostic , Tumeurs du pancréas/anatomopathologie , Tumeurs du cholédoque/chirurgie , Tumeurs du cholédoque/diagnostic , Tumeurs du cholédoque/anatomopathologie , Conduit cholédoque/chirurgie , Conduit cholédoque/anatomopathologie , Adulte d'âge moyen , Pancréatectomie/méthodes , Résultat thérapeutique , Sujet âgé , Tomodensitométrie/méthodesRÉSUMÉ
BACKGROUND: Inflammation plays a critical role in tumor development. Inflammatory cell infiltration and inflammatory mediator synthesis cause changes in the tumor microenvironment (TME) in several cancers, especially in intrahepatic cholangiocellular carcinoma (ICC). However, methods to ascertain the inflammatory state of patients using reliable biomarkers are still being explored. METHOD: We retrieved the RNA sequencing and somatic mutation analyses results and the clinical characteristics of 244 patients with ICC from published studies. We performed consensus clustering to identify the molecular subtypes associated with inflammation. We compared the prognostic patterns, clinical characteristics, somatic mutation profiles, and immune cell infiltration patterns across inflammatory subtypes. We performed quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) to confirm gene expression. We performed logistic regression analyses to construct a nomogram predicting the inflammatory status of patients with ICC. RESULTS: Our results confirmed that ICC can be categorized into an inflammation-high subtype (IHS) and an inflammation-low subtype (ILS). Patients from each group had distinct prognosis, clinical characteristics, and TME composition. Patients with ICC in the IHS group showed poorer prognosis owing to the immunosuppressive microenvironment and high frequency of KRAS and TP53 mutations. Cancer-associated fibroblast (CAF)-derived COLEC11 reduced myeloid inflammatory cell infiltration and attenuated inflammatory responses. The results of qRT-PCR and IHC experiments confirmed that COLEC11 expression levels were significantly reduced in tumor tissues compared to those in paracancerous tissues. Patients with ICC in the IHS group were more likely to respond to treatment with immune checkpoint inhibitors (ICIs) owing to their higher tumor mutational burden (TMB) scores, tumor neoantigen burden (TNB) scores, neoantigen counts, and immune checkpoint expression levels. Finally, we developed a nomogram to effectively predict the inflammatory status of patients with ICC based on their clinical characteristics and inflammatory gene expression levels. We evaluated the calibration, discrimination potential, and clinical utility of the nomogram. CONCLUSION: The inflammatory response in IHS is primarily induced by myeloid cells. COLEC11 can reduce the infiltration level of this group of cells, and myeloid inflammatory cells may be a novel target for ICC treatment. We developed a novel nomogram that could effectively predict the inflammatory state of patients with ICC, which will be useful for guiding individualized treatment plans.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Inflammation , Microenvironnement tumoral , Humains , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/génétique , Inflammation/anatomopathologie , Inflammation/génétique , Microenvironnement tumoral/immunologie , Mâle , Femelle , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/génétique , Adulte d'âge moyen , Pronostic , Mutation/génétique , Sujet âgé , Régulation de l'expression des gènes tumoraux , Nomogrammes , Reproductibilité des résultatsSujet(s)
Cholangiopancréatographie rétrograde endoscopique , Cholestase , Drainage , Humains , Drainage/méthodes , Cholangiopancréatographie rétrograde endoscopique/méthodes , Cholestase/étiologie , Cholestase/chirurgie , Cholestase/imagerie diagnostique , Cholestase/thérapie , Endoscopie digestive/méthodes , Mâle , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/imagerie diagnostique , Sujet âgé , FemelleRÉSUMÉ
BACKGROUND: Surgical therapy is the most optimal treatment for hepatocellular carcinoma (HCC) combined with bile duct tumor thrombus (BDTT) patients. However, whether to perform bile duct resection (BDR) is still controversial. The purpose of this multicenter research is to compare the effect of BDR on the prognosis of extrahepatic BDTT patients. METHODS: We collected the data of 111 HCC patients combined with extrahepatic BDTT who underwent radical hepatectomy from June 1, 2004 to December 31, 2021. Those patients had either received hepatectomy with extrahepatic bile duct resection (BDR group) or hepatectomy without bile duct resection (NBDR group). Inverse probability of treatment weighting (IPTW) was used to reduce the potential bias between two groups and balance the influence of confounding factors in baseline data. Then compare the prognosis between the two groups of patients. Cox regression model was used for univariate and multivariate analysis to further determine the independent risk factors that influence the prognosis of HCC-BDTT patients. RESULTS: There were 38 patients in the BDR group and 73 patients in the NBDR group. Before and after IPTW, there were no statistical significance in OS, RFS and intraoperative median blood loss between the two groups (all P > 0.05). Before IPTW, the median postoperative hospital stay in the NBDR group was shorter (P = 0.046) and the grade of postoperative complications was lower than BDR group (P = 0.014). After IPTW, there was no difference in postoperative hospital stay between the two groups (P > 0.05). The complication grade in the NBDR group was still lower than that in the BDR group (P = 0.046). The univariate analysis showed that TNM stage and portal vein tumor thrombus (PVTT) were significantly correlated with OS (both P < 0.05). Preoperative AFP level, TNM stage and prognostic nutritional index (PNI) were significantly correlated with postoperative RFS (all P < 0.05). Multivariate analysis showed that tumor TNM stage was an independent risk factor for the OS rate (P = 0.014). TNM stage, PNI and AFP were independent predictors of RFS after radical hepatectomy (all P < 0.05). CONCLUSIONS: For HCC-BDTT patients, hepatocellular carcinoma resection combined with choledochotomy to remove the tumor thrombus may benefit more.
Sujet(s)
Conduits biliaires extrahépatiques , Carcinome hépatocellulaire , Hépatectomie , Tumeurs du foie , Humains , Carcinome hépatocellulaire/chirurgie , Carcinome hépatocellulaire/anatomopathologie , Carcinome hépatocellulaire/mortalité , Carcinome hépatocellulaire/complications , Mâle , Femelle , Tumeurs du foie/chirurgie , Tumeurs du foie/anatomopathologie , Tumeurs du foie/mortalité , Tumeurs du foie/complications , Adulte d'âge moyen , Pronostic , Conduits biliaires extrahépatiques/chirurgie , Conduits biliaires extrahépatiques/anatomopathologie , Thrombose/chirurgie , Thrombose/étiologie , Thrombose/anatomopathologie , Études rétrospectives , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/mortalité , Sujet âgé , AdulteRÉSUMÉ
Prostate-specific membrane antigen (PSMA) targeted tracers show increased uptake in several malignancies, indicating a potential for peptide radioligand therapy. Intra-arterial injection of radiotracers can increase the therapeutic window. This study aimed to evaluate the feasibility of intra-arterial injection of [68Ga]Ga-PSMA-11 for intrahepatic cholangiocarcinoma and compare tracer uptake after intrahepatic arterial injection and intravenous injection. Three patients with intrahepatic cholangiocarcinoma received [68Ga]Ga-PSMA-11 through a hepatic arterial infusion pump, followed by positron emission tomography/computed tomography (PET/CT). Two-three days later, patients underwent PET/CT after intravenous [68Ga]Ga-PSMA-11 injection. All tumours showed higher uptake on the intra-arterial scan compared with the intravenous scan: the intra-arterial / intravenous standardised uptake value normalised by lean body mass ratios were 1.40, 1.46, and 1.54. Local intra-arterial PSMA injection is possible in patients with intrahepatic cholangiocarcinoma. Local injection increases tumour-to-normal tissue ratios, increasing the therapeutic window for theranostic applications. RELEVANCE STATEMENT: Intra-arterial Prostate specific membrane antigen (PSMA) injection increases the therapeutic window for potential theranostic application in intrahepatic cholangiocarcinoma. KEY POINTS: Three patients with intrahepatic cholangiocarcinoma underwent PET/CT after intra-arterial and intravenous injection of [68Ga]Ga-PSMA-11. Intra-arterial injection showed higher uptake than intravenous injection. PSMA-targeted imaging could be valuable for a subset of intrahepatic cholangiocarcinoma patients.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Radio-isotopes du gallium , Tomographie par émission de positons couplée à la tomodensitométrie , Humains , Cholangiocarcinome/imagerie diagnostique , Tomographie par émission de positons couplée à la tomodensitométrie/méthodes , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/traitement médicamenteux , Mâle , Adulte d'âge moyen , Sujet âgé , Radio-isotopes du gallium/administration et posologie , Artère hépatique/imagerie diagnostique , Étude de validation de principe , Isotopes du gallium , Injections artérielles , Femelle , Perfusions artérielles , Oligopeptides/administration et posologie , Études de faisabilité , Pompes à perfusion , Radiopharmaceutiques/administration et posologieRÉSUMÉ
BACKGROUND: Despite the recent advances in cancer treatment, the therapeutic options for patients with biliary tract cancer are still very limited and the prognosis very poor. More than 50% of newly diagnosed patients with biliary tract cancer are not amenable to curative surgical treatment and thus treated with palliative systemic treatment. Malignant bile duct obstructions in patients with perihilar and/or ductal cholangiocarcinoma (CCA) represents one of the most important challenges in the management of these patients, owning to the risk represented by developing life-threatening cholangitis which, in turn, limits the use of systemic treatment. For this reason, endoscopic stenting and/or bile duct decompression is the mainstay of treatment of these patients. Data on efficacy and safety of adding radiofrequency ablation (RFA) to biliary stenting is not conclusive. The aim of this multicenter, randomized trial is to evaluate the effect of intraductal RFA prior to bile duct stenting in patients with unresectable perihilar or ductal CCA undergoing palliative systemic therapy. METHODS/DESIGN: ACTICCA-2 is a multicenter, randomized, controlled, open-label, investigator-initiated trial. 120 patients with perihilar or ductal CCA with indication for biliary stenting and systemic therapy will be randomized 1:1 to receive either RFA plus bile duct stenting (interventional arm) or bile duct stenting alone (control arm). Patients will be stratified by trial site and tumor location (perihilar vs. ductal). Both arms receive palliative systemic treatment according to the local standard of care determined by a multidisciplinary tumorboard. The primary endpoint is time to first biliary event, which is determined by an increase of bilirubin to > 5 mg/dl and/or the occurrence of cholangitis leading to premature stent replacement and/or disruption of chemotherapy. Secondary endpoints include overall survival, safety according to NCI CTCAE v5, quality of life assessed by questionnaires (EORTC QLQ-C30 and QLQ-BIL21), clinical event rate at 6 months after RFA and total days of over-night stays in hospital. Follow-up for the primary endpoint will be 6 months, while survival assessment will be continued until end of study (maximum follow-up 30 month). All patients who are randomized and who underwent endoscopic stenting will be used for the primary endpoint analysis which will be conducted using a cause-specific Cox proportional hazards model with a frailty for trial site and fixed effects for the treatment group, tumor location, and stent material. DISCUSSION: ACTICCA-2 is a multicenter, randomized, controlled trial to assess efficacy and safety of adding biliary RFA to bile duct stenting in patients with CCA receiving palliative systemic treatment. TRIAL REGISTRATION: The study is registered with ClinicalTrials.gov (NCT06175845) and approved by the local ethics committee in Hamburg, Germany (2024-101232-BO-ff). This manuscript reflects protocol version 1 as of January 9th, 2024.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Ablation par radiofréquence , Endoprothèses , Humains , Cholangiocarcinome/thérapie , Cholangiocarcinome/chirurgie , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/thérapie , Ablation par radiofréquence/méthodes , Ablation par radiofréquence/effets indésirables , Soins palliatifs/méthodes , Mâle , Femelle , Qualité de vie , Ablation par cathéter/méthodes , Résultat thérapeutique , Sujet âgéRÉSUMÉ
Tumour morphology (tumour burden score (TBS)) and liver function (albumin-to-alkaline phosphatase ratio (AAPR)) have been shown to correlate with outcomes in intrahepatic cholangiocarcinoma (ICC). This study aimed to evaluate the combined predictive effect of TBS and AAPR on survival outcomes in ICC patients. We conducted a retrospective analysis using a multicentre database of ICC patients who underwent curative surgery from 2011 to 2018. The Kaplan-Meier method was employed to examine the relationship between a new index (combining TBS and AAPR) and long-term outcomes. The predictive efficacy of this index was compared to other conventional indicators. A total of 560 patients were included in the study. Based on TBS and AAPR stratification, patients were classified into three groups. Kaplan-Meier curves demonstrated that 124 patients with low TBS and high AAPR had the best overall survival (OS) and recurrence-free survival (RFS), while 170 patients with high TBS and low AAPR had the worst outcomes (log-rank p < 0.001). Multivariate analyses identified the combined index as an independent predictor of OS and RFS. Furthermore, the index showed superior accuracy in predicting OS and RFS compared to other conventional indicators. Collectively, this study demonstrated that the combination of liver function and tumour morphology provides a synergistic effect in evaluating the prognosis of ICC patients. The novel index combining TBS and AAPR effectively stratified postoperative survival outcomes in ICC patients undergoing curative resection.
Sujet(s)
Phosphatase alcaline , Tumeurs des canaux biliaires , Cholangiocarcinome , Charge tumorale , Humains , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/chirurgie , Cholangiocarcinome/sang , Cholangiocarcinome/mortalité , Femelle , Mâle , Phosphatase alcaline/sang , Adulte d'âge moyen , Pronostic , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/mortalité , Tumeurs des canaux biliaires/sang , Sujet âgé , Études rétrospectives , Estimation de Kaplan-Meier , Marqueurs biologiques tumoraux/sangSujet(s)
Antimétabolites antinéoplasiques , Tumeurs des canaux biliaires , Cholangiocarcinome , Désoxycytidine , , Hyperammoniémie , Humains , Cholangiocarcinome/traitement médicamenteux , Cholangiocarcinome/complications , Hyperammoniémie/induit chimiquement , Désoxycytidine/analogues et dérivés , Désoxycytidine/effets indésirables , Tumeurs des canaux biliaires/traitement médicamenteux , Tumeurs des canaux biliaires/complications , Antimétabolites antinéoplasiques/effets indésirables , Mâle , Adulte d'âge moyen , Sujet âgé , FemelleRÉSUMÉ
BACKGROUND: The advances in deep learning-based pathological image analysis have invoked tremendous insights into cancer prognostication. Still, lack of interpretability remains a significant barrier to clinical application. METHODS: We established an integrative prognostic neural network for intrahepatic cholangiocarcinoma (iCCA), towards a comprehensive evaluation of both architectural and fine-grained information from whole-slide images. Then, leveraging on multi-modal data, we conducted extensive interrogative approaches to the models, to extract and visualize the morphological features that most correlated with clinical outcome and underlying molecular alterations. RESULTS: The models were developed and optimized on 373 iCCA patients from our center and demonstrated consistent accuracy and robustness on both internal (n = 213) and external (n = 168) cohorts. The occlusion sensitivity map revealed that the distribution of tertiary lymphoid structures, the geometric traits of the invasive margin, the relative composition of tumor parenchyma and stroma, the extent of necrosis, the presence of the disseminated foci, and the tumor-adjacent micro-vessels were the determining architectural features that impacted on prognosis. Quantifiable morphological vector extracted by CellProfiler demonstrated that tumor nuclei from high-risk patients exhibited significant larger size, more distorted shape, with less prominent nuclear envelope and textural contrast. The multi-omics data (n = 187) further revealed key molecular alterations left morphological imprints that could be attended by the network, including glycolysis, hypoxia, apical junction, mTORC1 signaling, and immune infiltration. CONCLUSIONS: We proposed an interpretable deep-learning framework to gain insights into the biological behavior of iCCA. Most of the significant morphological prognosticators perceived by the network are comprehensible to human minds.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Apprentissage profond , Humains , Cholangiocarcinome/anatomopathologie , Pronostic , Tumeurs des canaux biliaires/anatomopathologie , Mâle , Femelle , Adulte d'âge moyen , Traitement d'image par ordinateur/méthodes , Sujet âgéRÉSUMÉ
OBJECTIVE: Our study aims to evaluate the predictive accuracy of functional liver remnant volume (FLRV) in post-hepatectomy liver failure (PHLF) among surgically-treated jaundiced patients with hilar cholangiocarcinoma (HCCA). METHODS: We retrospectively reviewed surgically-treated jaundiced patients with HCCA between June, 2000 and June, 2018. The correlation between FRLV and PHLF were analyzed. The optimal cut off value of FLRV in jaundiced HCCA patients was also identified and its impact was furtherly evaluated. RESULTS: A total of 224 jaundiced HCCA patients who received a standard curative resection (43 patients developed PHLF) were identified. Patients with PHLF shared more aggressive clinic-pathological features and were generally in a more advanced stage than those without PHLF. An obvious inconsistent distribution of FLRV in patients with PHLF and those without PHLF were detected. FLRV (continuous data) had a high predictive accuracy in PHLF. The newly-acquired cut off value (FLRV = 53.5%, sensitivity = 81.22%, specificity = 81.4%) showed a significantly higher predictive accuracy than conventional FLRV cut off value (AUC: 0.81 vs. 0.60, p < 0.05). Moreover, patients with FLRV lower than 53.5% also shared a significantly higher major morbidity rate as well as a worse prognosis, which were not detected for FLRV of 40%. CONCLUSION: For jaundiced patients with HCCA, a modified FLRV of 53.5% is recommended due to its great impact on PHLF, as well as its correlation with postoperative major morbidities as well as overall prognosis, which might help clinicians to stratify patients with different therapeutic regimes and outcomes. Future multi-center studies for training and validation are required for further validation.
Sujet(s)
Tumeurs des canaux biliaires , Hépatectomie , Ictère , Tumeur de Klatskin , Défaillance hépatique , Humains , Mâle , Hépatectomie/effets indésirables , Femelle , Adulte d'âge moyen , Tumeur de Klatskin/chirurgie , Tumeur de Klatskin/anatomopathologie , Études rétrospectives , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/anatomopathologie , Défaillance hépatique/étiologie , Défaillance hépatique/prévention et contrôle , Chine/épidémiologie , Ictère/étiologie , Foie/chirurgie , Foie/anatomopathologie , Sujet âgé , Complications postopératoires/étiologie , Complications postopératoires/prévention et contrôle , Complications postopératoires/épidémiologie , Pronostic , Adulte , Taille d'organeRÉSUMÉ
BACKGROUND: The surgical management of perihilar carcinoma (pCCA) is still subject of ongoing debate. To provide more clarity, this study was conducted to evaluate outcomes related to the side and extent of heatectomy in patients with pCAA. METHODS: A total of 32 patients with curative resection for pCCA were identified from our prospective database. Short-and long-term clinical outcome data and histopathological results were compared between right-sided (R-H) and left-sided (L-H) hepatectomy. RESULTS: Nine patients (28.13%) underwent left-sided hepatectomy while a right-sided hepatectomy was accomplished in 23 patients (71.87%). In the R-H group hepatic conditioning of the future liver remnant (FLR) prior to extended resection was necessary in 13 cases (56.52%), and simultaneous pancreaticoduodenectomy was performed in 5 patients (21.74%). The arterial and portal venous reconstruction rates were 17.39% and 11.11% (P=1.00), and 60.87% and 33.33% (P=0.243) in the R-H and L-H groups, respectively. No statistically significant differences in short-term morbidity and mortality between both groups were observed. The rate of R0 resections was comparable (R-H: 78.26% versus L-H: 66.67%; P=0.654) resulting in similar long-term overall and disease-free survival rates after right-and left hepatectomy. CONCLUSIONS: In patients with pCCA, both right- and left-sided resections appear to be safe and feasible options with similar postoperative morbidity and oncologic outcomes. Consecutively, the ideal surgical approach should be patient-tailored based on anatomical considerations and the functional future liver capacity.
Sujet(s)
Tumeurs des canaux biliaires , Hépatectomie , Tumeur de Klatskin , Humains , Mâle , Femelle , Adulte d'âge moyen , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/mortalité , Tumeur de Klatskin/chirurgie , Tumeur de Klatskin/anatomopathologie , Tumeur de Klatskin/mortalité , Résultat thérapeutique , Sujet âgé , Facteurs temps , Adulte , DuodénopancréatectomieRÉSUMÉ
Clonorchis sinensis, Opisthorchis viverrini and O. felineus are liver flukes of human and animal pathogens occurring across much of Europe and Asia. Nevertheless, they are often underestimated compared to other, better known neglected diseases in spite of the fact that many millions of people are infected and hundreds of millions are at risk. This is possibly because of the chronic nature of the infection and disease and that it takes several decades prior to a life-threatening pathology to develop. Several studies in the past decade have provided more information on the molecular biology of the liver flukes which clearly lead to better understanding of parasite biology, systematics and population genetics. Clonorchiasis and opisthorchiasis are characterized by a chronic infection that induces hepatobiliary inflammation, especially periductal fibrosis, which can be detected by ultrasonography. These chronic inflammations eventually lead to cholangiocarcinoma (CCA), a usually fatal bile duct cancer that develops in some infected individuals. In Thailand alone, opisthorchiasis-associated CCA kills up to 20,000 people every year and is therefore of substantial public health importance. Its socioeconomic impacts on impoverished families and communities are considerable. To reduce hepatobiliary morbidity and CCA, the primary intervention measures focus on control and elimination of the liver fluke. Accurate diagnosis of liver fluke infections in both human and other mammalian, snail and fish intermediate hosts is important for achieving these goals. While the short-term goal of liver fluke control can be achieved by praziquantel chemotherapy, a comprehensive health education package targeting school children is believed to be more beneficial for a long-term goal/solution. It is recommended that transdisciplinary research or multisectoral control approach including one health and/or eco health intervention strategy should be applied to combat the liver flukes and hence contribute to reduction of CCA in endemic areas.
Sujet(s)
Clonorchiase , Clonorchis sinensis , Opisthorchiase , Opisthorchis , Animaux , Humains , Opisthorchis/pathogénicité , Opisthorchiase/épidémiologie , Opisthorchiase/parasitologie , Clonorchiase/épidémiologie , Clonorchiase/parasitologie , Clonorchiase/prévention et contrôle , Clonorchiase/traitement médicamenteux , Clonorchis sinensis/pathogénicité , Clonorchis sinensis/génétique , Clonorchis sinensis/physiologie , Tumeurs des canaux biliaires/parasitologie , Tumeurs des canaux biliaires/épidémiologie , Tumeurs des canaux biliaires/anatomopathologie , Cholangiocarcinome/parasitologie , Cholangiocarcinome/épidémiologieRÉSUMÉ
Subsequent to a medical examination, a 61-year-old male was referred to our hospital with jaundice. He was diagnosed with intrahepatic cholangiocarcinoma involving the hepatic hilum and was referred to our department to undergo a left trisectionectomy of the liver, extrahepatic bile duct resection, and regional lymphadenectomy. He was discharged on postoperative day 39 without liver failure. Two months postoperatively, positron-emission tomography/computed tomography(PET/ CT)indicated recurrences in the bone, and paraaortic lymph node. Gemcitabine and cisplatin combination first-line therapy was administered. Disease progression occurred after 4 courses of therapy. Gene panel testing was performed and the patient was switched to pembrolizumab owing to high microsatellite instability. After 2 courses of pembrolizumab, notable shrinkage of the paraaortic lymph node recurrence was confirmed on computed tomography as well as a partial response. PET-CT revealed disappearance of abnormal accumulation in all lesions at 20 months postoperatively. This has been sustained for 24 months following surgery without remarkable immune-related side-effects.